{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:41:18Z","timestamp":1793900478381,"version":"4.8.0"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"am","delay-in-days":208,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["CRG\/2019\/004842"],"award-info":[{"award-number":["CRG\/2019\/004842"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008478","name":"Wake Forest School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011706","name":"National Agri-Food Biotechnology Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011706","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.pharmthera.2021.107877","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T18:15:22Z","timestamp":1619115322000},"page":"107877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Effect of hepcidin antagonists on anemia during inflammatory disorders"],"prefix":"10.1016","volume":"226","author":[{"given":"Poonam","family":"Sagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanzin","family":"Angmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Sandhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Rishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hariom","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin Kumar","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2021.107877_bb0005","first-page":"164","article-title":"Review on iron and its importance for human health","volume":"19","author":"Abbaspour","year":"2014","journal-title":"Journal of Research in Medical Sciences\u202f: The Official Journal of Isfahan University of Medical Sciences"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejr.2017.09.004","article-title":"The effectiveness of etanercept and adalimumab on anemia of chronic disease and serum hepcidin in patients with rheumatoid arthritis, a comparative study","volume":"40","author":"Abu-Zaid","year":"2018","journal-title":"The Egyptian Rheumatologist"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3324\/haematol.10545","article-title":"Molecular mechanism of hepcidin deficiency in a patient with juvenile hemochromatosis","volume":"92","author":"Alexandra","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bjbas.2014.05.007","article-title":"The determinants of hepcidin level in chronic kidney disease and hemodialysis Saudi patients","volume":"3","author":"Ali","year":"2014","journal-title":"Beni-Suef University Journal of Basic and Applied Sciences"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cmet.2014.07.007","article-title":"Resistance of ferroportin to hepcidin binding causes exocrine pancreatic failure and fatal iron overload","volume":"20","author":"Altamura","year":"2014","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/j.2040-4603.2013.tb00494.x","article-title":"Iron homeostasis in the liver","volume":"3","author":"Anderson","year":"2013","journal-title":"Comprehensive Physiology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0035","doi-asserted-by":"crossref","first-page":"1559S","DOI":"10.3945\/ajcn.117.155804","article-title":"Current understanding of iron homeostasis","volume":"106","author":"Anderson","year":"2017","journal-title":"The American Journal of Clinical Nutrition"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1590-8658(00)80045-6","article-title":"Intestinal iron absorption: Current concepts circa 2000","volume":"32","author":"Andrews","year":"2000","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0045","doi-asserted-by":"crossref","first-page":"17684","DOI":"10.1038\/s41598-018-35992-2","article-title":"Novel liposome eencapsulated guanosine di phosphate based therapeutic target against anemia of inflammation","volume":"8","author":"Angmo","year":"2018","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0050","doi-asserted-by":"crossref","first-page":"40097","DOI":"10.1038\/srep40097","article-title":"Identification of guanosine 5\u2032-diphosphate as potential Iron mobilizer: Preventing the hepcidin-ferroportin interaction and modulating the interleukin-6\/Stat-3 pathway","volume":"7","author":"Angmo","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0055","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","article-title":"Erythroferrone inhibits the induction of hepcidin by BMP6","volume":"132","author":"Arezes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0060","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1053\/j.gastro.2009.09.048","article-title":"Iron-induced expression of bone morphogenic protein 6 in intestinal cells is the main regulator of hepatic Hepcidin expression in vivo","volume":"138","author":"Arndt","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0065","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-05-786590","article-title":"Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin","volume":"131","author":"Aschemeyer","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0070","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0075","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/MPG.0000000000001650","article-title":"Changes in hepcidin and hemoglobin after anti-TNF-alpha therapy in children and adolescents with Crohn disease","volume":"66","author":"Atkinson","year":"2018","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0080","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1172\/JCI31342","article-title":"Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance","volume":"117","author":"Babitt","year":"2007","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0085","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V128.22.1280.1280","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-ferroportin antibody in patients with anemia due to chronic renal failure","volume":"128","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0090","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.3390\/nu11102424","article-title":"Anemia of inflammation with an emphasis on chronic kidney disease","volume":"11","author":"Begum","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0095","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.gastro.2006.07.007","article-title":"Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH","volume":"131","author":"Bekri","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood-2012-02-411470","article-title":"Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1\/5\/8 signaling","volume":"120","author":"Besson-Fournier","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0105","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/febs.12825","article-title":"A structural model of human ferroportin and of its iron binding site","volume":"281","author":"Bonaccorsi Di Patti","year":"2014","journal-title":"FEBS Journal"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0110","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bph.13433","article-title":"Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects","volume":"173","author":"Boyce","year":"2016","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0115","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3324\/haematol.2019.232124","article-title":"Iron metabolism and iron disorders revisited in the hepcidin era","volume":"105","author":"Camaschella","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0120","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.chembiol.2010.12.009","article-title":"Article understanding the structure \/ activity relationships of the iron regulatory peptide hepcidin","volume":"18","author":"Clark","year":"2011","journal-title":"Chemistry & Biology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0125","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/blood-2013-06-505792","article-title":"A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates","volume":"122","author":"Cooke","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0130","doi-asserted-by":"crossref","first-page":"E1236","DOI":"10.1152\/ajpendo.00022.2010","article-title":"Dietary iron restriction or iron chelation protects from diabetes and loss of \u03b2-cell function in the obese (ob\/ob lep\u2212\/\u2212) mouse","volume":"298","author":"Cooksey","year":"2010","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0135","doi-asserted-by":"crossref","first-page":"41163","DOI":"10.1074\/jbc.M202653200","article-title":"C\/EBP\u03b1 regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism: Cross-talk between C\/EBP pathway and iron metabolism","volume":"277","author":"Courselaud","year":"2002","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0140","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.12998\/wjcc.v7.i15.1926","article-title":"Extrahepatic hepcidin production: The intriguing outcomes of recent years","volume":"7","author":"Daher","year":"2019","journal-title":"World Journal of Clinical Cases"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5045\/br.2013.48.1.10","article-title":"Role of hepcidin in the pathophysiology and diagnosis of anemia","volume":"48","author":"D'Angelo","year":"2013","journal-title":"Blood Research"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0150","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1073\/pnas.0900453106","article-title":"Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2","volume":"106","author":"De Domenico","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0155","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1091\/mbc.e07-01-0060","article-title":"The molecular mechanism of hepcidin-mediated ferroportin down-regulation","volume":"18","author":"De Domenico","year":"2007","journal-title":"Molecular Biology of the Cell"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0160","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1172\/JCI42011","article-title":"Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice","volume":"120","author":"De Domenico","year":"2010","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0165","first-page":"3","article-title":"AMPK is not required for the effect of metformin on the inhibition of BMP6-induced hepcidin gene expression in hepatocytes","author":"Deschemin","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0170","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1111\/hdi.12542","article-title":"Overview of iron metabolism in health and disease","volume":"21","author":"Dev","year":"2017","journal-title":"Hemodialysis International"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nchembio.1416","article-title":"The role of iron and reactive oxygen species in cell death","volume":"10","author":"Dixon","year":"2014","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0180","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood-2014-03-559484","article-title":"Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans","volume":"124","author":"van Eijk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0185","series-title":"Biochemistry, Iron Absorption","author":"Ems","year":"2020"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0190","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-87-6-710","article-title":"Iron balance in hemodialysis patients","volume":"87","author":"Eschbach","year":"1977","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0195","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cbic.200300663","article-title":"Spiegelmers: Biostable aptamers","volume":"4","author":"Eulberg","year":"2003","journal-title":"ChemBioChem"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3180001","article-title":"The lipocalin protein family: Structure and function","volume":"318","author":"Flower","year":"1996","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0205","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3324\/haematol.2013.084624","article-title":"Manipulation of the hepcidin pathway for therapeutic purposes","volume":"98","author":"Fung","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0210","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/mol.112.083428","article-title":"High-throughput screening of small molecules identifies hepcidin antagonists","volume":"83","author":"Fung","year":"2013","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0215","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.bbamcr.2006.03.014","article-title":"Regulation of iron acquisition and iron distribution in mammals","volume":"1763","author":"Ganz","year":"2006","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0220","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood-2013-08-521625","article-title":"Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus","volume":"123","author":"Gardenghi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0225","series-title":"Poster presentations","article-title":"FRI0242 Association between clinical and radiographic responses, and physical function in a phase 3 study of sarilumab plus methotrexate in patients with active, moderate-to-severe rheumatoid arthritis","author":"Genovese","year":"2017"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0230","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3899\/jrheum.120687","article-title":"Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: A cumulative analysis of up to 4.6 years of exposure","volume":"40","author":"Genovese","year":"2013","journal-title":"The Journal of Rheumatology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0235","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1158\/1538-7445.AM2014-3847","article-title":"Abstract 3847: The anti-hepcidin Spiegelmer\u00ae Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study","volume":"74","author":"Georgiev","year":"2014","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0240","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2008.003541","article-title":"Cross-talk between the mitogen activated protein kinase and bone morphogenetic protein\/hemojuvelin pathways is required for the induction of hepcidin by holotransferrin in primary mouse hepatocytes","volume":"94","author":"Guillemette","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0245","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.hoc.2017.11.009","article-title":"Ineffective erythropoiesis: anemia and iron overload","volume":"32","author":"Gupta","year":"2018","journal-title":"Hematology\/Oncology Clinics"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0250","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1677\/JOE-07-0528","article-title":"Pancreatic \u03b2-cells express hepcidin, an iron-uptake regulatory peptide","volume":"197","author":"Hasan","year":"2008","journal-title":"Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/ph12040170","article-title":"Therapeutic advances in regulating the hepcidin\/ferroportin axis","volume":"12","author":"Hawula","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0260","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.hoc.2014.04.009","article-title":"Iron-refractory iron deficiency anemia (IRIDA)","volume":"28","author":"Heeney","year":"2014","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0265","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0270","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bph.14143","article-title":"Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey","volume":"175","author":"Hohlbaum","year":"2018","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0275","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1074\/jbc.M114.604397","article-title":"Small molecules dorsomorphin and LDN-193189 inhibit myostatin\/GDF8 signaling and promote functional myoblast differentiation","volume":"290","author":"Horbelt","year":"2015","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2017.10.001","article-title":"Aspirin increases ferroportin 1 expression by inhibiting hepcidin via the JAK\/STAT3 pathway in interleukin 6-treated PC-12 cells","volume":"662","author":"Huang","year":"2018","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0285","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gutjnl-2014-307720","article-title":"Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants","volume":"64","author":"Jaeggi","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0290","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/0971-4065.70840","article-title":"Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy","volume":"20","author":"Jha","year":"2010","journal-title":"Indian Journal of Nephrology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0295","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1756283X11398736","article-title":"Diagnosis and management of iron deficiency anemia in the 21st century","volume":"4","author":"Johnson-Wimbley","year":"2011","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/ph11040127","article-title":"Hepcidin therapeutics","volume":"11","author":"Katsarou","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0305","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism","volume":"46","author":"Kautz","year":"2014","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0310","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fimmu.2017.00073","article-title":"From the cradle to the grave: The role of macrophages in erythropoiesis and erythrophagocytosis","volume":"8","author":"Klei","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0315","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-008-0120-5","article-title":"Body iron metabolism and pathophysiology of iron overload","volume":"88","author":"Kohgo","year":"2008","journal-title":"International Journal of Hematology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0320","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1097\/MIB.0000000000000417","article-title":"The influence of anti-tumor necrosis factor agents on hemoglobin levels of patients with inflammatory bowel disease","volume":"21","author":"Koutroubakis","year":"2015","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0325","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.3324\/haematol.2015.140772","article-title":"Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels","volume":"101","author":"Kovac","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0330","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0014-5793(00)01920-7","article-title":"LEAP-1, a novel highly disul \u00a2 de-bonded human peptide, exhibits antimicrobial activity 1","volume":"480","author":"Krause","year":"2000","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0335","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1208\/s12248-016-9886-1","article-title":"Pharmacodynamic model of hepcidin regulation of iron homeostasis in cynomolgus monkeys","volume":"18","author":"Krzyzanski","year":"2016","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0340","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/fcp.12288","article-title":"Curcuma decreases serum hepcidin levels in healthy volunteers: A placebo-controlled, randomized, double-blind, cross-over study","volume":"31","author":"Lain\u00e9","year":"2017","journal-title":"Fundamental & Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.00159","article-title":"MyD88 adaptor protein is required for appropriate hepcidin induction in response to dietary iron overload in mice","volume":"9","author":"Layoun","year":"2018","journal-title":"Frontiers in Physiology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0350","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000504850","article-title":"Treatment of renal anemia with roxadustat: Advantages and achievement","volume":"6","author":"Li","year":"2020","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0355","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood-2007-04-087593","article-title":"Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2\/4","volume":"110","author":"Lin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0360","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1089\/jmf.2012.2231","article-title":"Polysaccharide isolated from Angelica sinensis inhibits hepcidin expression in rats with iron deficiency anemia","volume":"15","author":"Liu","year":"2012","journal-title":"Journal of Medicinal Food"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0365","doi-asserted-by":"crossref","first-page":"1681S","DOI":"10.3945\/ajcn.117.156042","article-title":"Excess iron intake as a factor in growth, infections, and development of infants and young children","volume":"106","author":"L\u00f6nnerdal","year":"2017","journal-title":"The American Journal of Clinical Nutrition"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0370","doi-asserted-by":"crossref","DOI":"10.1097\/MEG.0b013e32832b125c","article-title":"Infliximab in clinical routine: Experience with Crohn\u2019s disease and biomarkers of inflammation over 5 years","volume":"21","author":"L\u00f6nnkvist","year":"2009","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0375","first-page":"199","article-title":"Thiamine tetrahydrofurfuryl disulfide: A little known theraputic agent","volume":"10","author":"Lonsdale","year":"2004","journal-title":"Medical Science Monitor"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0380","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2215\/CJN.03840907","article-title":"Novel erythropoiesis-stimulating agents: A new era in anemia management","volume":"3","author":"Macdougall","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0385","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfv182.08","article-title":"Fp660pharmacokinetics and pharmacodynamics of lexaptepid, a novel anti-hepcidin molecule, in ESA-resistant haemodialysis patients","volume":"30","author":"Macdougall","year":"2015","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0390","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1126\/science.1057206","article-title":"An iron-regulated ferric reductase associated with the absorption of dietary iron","volume":"291","author":"McKie","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0395","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1017\/S1368980008002401","article-title":"Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993-2005","volume":"12","author":"McLean","year":"2009","journal-title":"Public Health Nutrition"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0400","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1210\/en.2006-1331","article-title":"The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation","volume":"148","author":"Merle","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0405","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood.V126.23.536.536","volume":"126","author":"Moebius","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0410","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/ptr.6118","article-title":"An investigation of the effects of curcumin on iron overload, hepcidin level, and liver function in \u03b2-thalassemia major patients: A double-blind randomized controlled clinical trial","volume":"32","author":"Mohammadi","year":"2018","journal-title":"Phytotherapy Research"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0415","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1021\/cb300655w","article-title":"Development of an ALK2-biased BMP type I receptor kinase inhibitor","volume":"8","author":"Mohedas","year":"2013","journal-title":"ACS Chemical Biology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0420","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/ajcn\/84.4.822","article-title":"Extruded rice fortified with micronized ground ferric pyrophosphate reduces iron deficiency in Indian schoolchildren: A double-blind randomized controlled trial","volume":"84","author":"Moretti","year":"2006","journal-title":"The American Journal of Clinical Nutrition"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0425","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/156482651203300410","article-title":"Rice fortification: An emerging opportunity to contribute to the elimination of vitamin and mineral deficiency worldwide","volume":"33","author":"Muthayya","year":"2012","journal-title":"Food and Nutrition Bulletin"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0430","doi-asserted-by":"crossref","first-page":"750643","DOI":"10.1155\/2010\/750643","article-title":"Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias","volume":"2010","author":"Nemeth","year":"2010","journal-title":"Advances in Hematology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0435","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.hoc.2014.04.005","article-title":"Anemia of inflammation","volume":"28","author":"Nemeth","year":"2014","journal-title":"Hematology\/Oncology Clinics of North America"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0440","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2005-05-2049","article-title":"The N-terminus of hepcidin is essential for its interaction with ferroportin: Structure-function study","volume":"107","author":"Nemeth","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0445","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0450","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","article-title":"Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein","volume":"101","author":"Nemeth","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/nu8080494","article-title":"Iron fortification of foods for infants and children in low-income countries: Effects on the gut microbiome, gut inflammation, and diarrhea","volume":"8","author":"Paganini","year":"2016","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0460","doi-asserted-by":"crossref","first-page":"1688S","DOI":"10.3945\/ajcn.117.156067","article-title":"The effects of iron fortification and supplementation on the gut microbiome and diarrhea in infants and children: A review","volume":"106","author":"Paganini","year":"2017","journal-title":"The American Journal of Clinical Nutrition"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0465","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1182\/blood-2006-06-028787","article-title":"Suppression of hepcidin during anemia requires erythropoietic activity","volume":"108","author":"Pak","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0470","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fnut.2018.00103","article-title":"Inherited disorders of Iron overload","volume":"5","author":"Pantopoulos","year":"2018","journal-title":"Frontiers in Nutrition"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0475","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00394-012-0339-z","article-title":"The effect of high doses of folic acid and iron supplementation in early-to-mid pregnancy on prematurity and fetal growth retardation: The mother\u2013child cohort study in Crete, Greece (Rhea study)","volume":"52","author":"Papadopoulou","year":"2013","journal-title":"European Journal of Nutrition"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0480","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0485","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1074\/jbc.M008922200","article-title":"Hepcidin, a urinary antimicrobial peptide synthesized in the liver","volume":"276","author":"Park","year":"2001","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0490","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00500-z","article-title":"Hepcidin is regulated by promoter-associated histone acetylation and HDAC3","volume":"8","author":"Pasricha","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0495","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-nutr-071715-050731","article-title":"Regulation of Hepcidin by erythropoiesis: The story so far","volume":"36","author":"Pasricha","year":"2016","journal-title":"Annual Review of Nutrition"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0500","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2010.037960","article-title":"Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors","volume":"96","author":"Pasricha","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0505","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2007-08-106195","article-title":"Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C\/EBP\u03b1","volume":"111","author":"Pinto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0510","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2014.00086","article-title":"Hepcidin antagonists for potential treatments of disorders with hepcidin excess","volume":"5","author":"Poli","year":"2014","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0515","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood-2010-06-289082","article-title":"Heparin: A potent inhibitor of hepcidin expression in vitro and in vivo","volume":"117","author":"Poli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0520","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s12035-014-8671-3","article-title":"Lipopolysaccharides upregulate hepcidin in neuron via microglia and the IL-6\/STAT3 signaling pathway","volume":"50","author":"Qian","year":"2014","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0525","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3945\/ajcn.110.007179","article-title":"Micronized ferric pyrophosphate supplied through extruded rice kernels improves body iron stores in children: A double-blind, randomized, placebo-controlled midday meal feeding trial in Indian schoolchildren","volume":"94","author":"Radhika","year":"2011","journal-title":"The American Journal of Clinical Nutrition"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0530","series-title":"Cross-talk between the mitogen activated protein kinase and bone morphogenetic protein \/ hemojuvelin pathways is required for the induction of hepcidin by holotransferrin in primary mouse hepatocytes","first-page":"765","author":"Ramey","year":"2009"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0535","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000471838","article-title":"Hepcidin: Homeostasis and diseases related to Iron metabolism","volume":"137","author":"Reichert","year":"2017","journal-title":"Acta Haematologica"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212023","article-title":"First-in-human phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis","volume":"14","author":"Renders","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0545","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.febslet.2013.11.006","article-title":"Anticalins: Exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins","volume":"588","author":"Richter","year":"2014","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BSR20150014","article-title":"Hepcidin: Regulation of the master iron regulator","volume":"35","author":"Rishi","year":"2015","journal-title":"Bioscience Reports"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0555","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pharmthera.2014.09.004","article-title":"The iron-regulatory hormone hepcidin: A possible therapeutic target?","volume":"146","author":"Rochette","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0560","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.tips.2014.01.004","article-title":"The pathophysiology and pharmacology of hepcidin","volume":"35","author":"Ruchala","year":"2014","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0565","series-title":"Effect of oral administration of docohexanoic acid on anemia and inflammation in hemodialysis patients: A randomized controlled clinical trial","author":"Ruperto","year":"2020"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0570","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/08880018.2016.1157229","article-title":"Iron-refractory iron deficiency anemia (IRIDA) cases with 2 novel TMPRSS6 mutations","volume":"33","author":"Sal","year":"2016","journal-title":"Pediatric Hematology and Oncology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0575","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3945\/an.116.013961","article-title":"Regulation of the iron homeostatic hormone hepcidin","volume":"8","author":"Sangkhae","year":"2017","journal-title":"Advances in Nutrition (Bethesda, Md.)"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0580","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3390\/ijms13021497","article-title":"Molecular diagnostic and pathogenesis of hereditary hemochromatosis","volume":"13","author":"Santos","year":"2012","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0585","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072126","article-title":"Effect of vedolizumab on anemia of chronic disease in patients with inflammatory bowel diseases","volume":"9","author":"Scarozza","year":"2020","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0590","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kex513","article-title":"Physiological effects of modulating the interleukin-6 axis","volume":"57","author":"Schett","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0595","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bcmd.2009.03.008","article-title":"Activation and inactivation of the iron hormone hepcidin: Biochemical characterization of prohepcidin cleavage and sequential degradation to N-terminally truncated hepcidin isoforms","volume":"43","author":"Schranz","year":"2009","journal-title":"Blood Cells, Molecules, and Diseases"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0600","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/gut.2011.241208","article-title":"Hepcidin is localised in gastric parietal cells, regulates acid secretion and is induced by <em>Helicobacter pylori<\/em> infection","volume":"61","author":"Schwarz","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0605","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood-2012-09-456756","article-title":"The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys","volume":"121","author":"Schwoebel","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0610","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4196\/kjpp.2009.13.2.131","article-title":"Janus kinase 2 inhibitor AG490 inhibits the STAT3 signaling pathway by suppressing protein translation of gp130","volume":"13","author":"Seo","year":"2009","journal-title":"The Korean Journal of Physiology & Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038136","article-title":"Tumor necrosis factor \u03b1 inhibits expression of the iron regulating hormone hepcidin in murine models of innate colitis","volume":"7","author":"Shanmugam","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0620","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/ejcn.2014.248","article-title":"Association of oral iron supplementation with birth outcomes in non-anaemic south Indian pregnant women","volume":"69","author":"Shastri","year":"2015","journal-title":"European Journal of Clinical Nutrition"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0625","doi-asserted-by":"crossref","DOI":"10.15562\/bmj.v6i1.410","article-title":"Eicosapentaenoic acid and docosahexaenoic acid in fish oil capsule supplementation in obese children decreases serum interleukin-6 and hepcidin and improves iron status","volume":"6","author":"Sidiartha","year":"2017","journal-title":"Bali Medical Journal"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0630","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar4323","article-title":"Comparative evaluation of the effects of treatment with tocilizumab and TNF-\u03b1 inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0635","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1189\/jlb.0407216","article-title":"Expression and localization of hepcidin in macrophages: A role in host defense against tuberculosis","volume":"82","author":"Sow","year":"2007","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0640","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1182\/blood-2011-03-339952","article-title":"Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice","volume":"118","author":"Steinbicker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0645","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1016\/j.febslet.2011.03.023","article-title":"Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases","volume":"585","author":"T, T., & M, N","year":"2011","journal-title":"FEBS Letters"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0650","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/s10165-012-0799-2","article-title":"JAK inhibitor tofacitinib for treating rheumatoid arthritis: From basic to clinical","volume":"23","author":"Tanaka","year":"2013","journal-title":"Modern Rheumatology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0655","doi-asserted-by":"crossref","first-page":"10289","DOI":"10.1073\/pnas.0603124103","article-title":"Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6","volume":"103","author":"Truksa","year":"2006","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0660","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/jnc.12244","article-title":"Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells","volume":"126","author":"Urrutia","year":"2013","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0665","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","article-title":"A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia","volume":"10","author":"Vadhan-Raj","year":"2017","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0670","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7326\/M19-2945","article-title":"Effects of interleukin-1\u03b2 inhibition on incident anemia","volume":"172","author":"Vallurupalli","year":"2020","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0675","doi-asserted-by":"crossref","DOI":"10.3390\/nu5072289","article-title":"Multi-copper oxidases and human iron metabolism","volume":"5","author":"Vashchenko","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0680","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of Ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0685","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT signaling in immunity and disease","volume":"194","author":"Villarino","year":"2015","journal-title":"The Journal of Immunology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0690","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2006-07-033969","article-title":"STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation","volume":"109","author":"Vittoria","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0695","doi-asserted-by":"crossref","first-page":"18354","DOI":"10.1074\/jbc.M117.801795","article-title":"Matriptase-2 suppresses hepcidin expression by cleaving multiple components of the hepcidin induction pathway","volume":"292","author":"Wahedi","year":"2017","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0700","first-page":"51","article-title":"The regulation of Iron absorption and homeostasis","volume":"37","author":"Wallace","year":"2016","journal-title":"The Clinical Biochemist. Reviews"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0705","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2018-06-815894","article-title":"Liver iron sensing and body iron homeostasis","volume":"133","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0710","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/ars.2016.6846","article-title":"AMPK serves as a therapeutic target against anemia of inflammation","volume":"27","author":"Wang","year":"2017","journal-title":"Antioxidants & Redox Signaling"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0715","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2005.10.010","article-title":"A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression","volume":"2","author":"Wang","year":"2005","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0720","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.gendis.2014.07.005","article-title":"Bone morphogenetic protein (BMP) signaling in development and human diseases","volume":"1","author":"Wang","year":"2014","journal-title":"Genes Dis"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0725","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.bbamcr.2012.03.004","article-title":"Ferroportin-mediated iron transport: Expression and regulation","volume":"1823","author":"Ward","year":"2012","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0730","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"133","author":"Weiss","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0735","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.3748\/wjg.14.4101","article-title":"Mechanisms of heme iron absorption: Current questions and controversies","volume":"14","author":"West","year":"2008","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0740","series-title":"Basic science in obstetrics and gynaecology (Fourth Edition)","first-page":"173","article-title":"Chapter ten - physiology","author":"Williams","year":"2010"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0745","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1309\/LMF28S2GIMXNWHMM","article-title":"The molecular biology of human Iron metabolism","volume":"45","author":"Winter","year":"2014","journal-title":"Laboratory Medicine"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0750","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1182\/blood.V122.21.3433.3433","article-title":"LY2928057, an antibody targeting ferroportin, is a potent inhibitor of Hepcidin activity and increases Iron mobilization in normal cynomolgus monkeys","volume":"122","author":"Witcher","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0755","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1208\/s12248-010-9222-0","article-title":"Pharmacokinetics of anti-hepcidin monoclonal antibody ab 12B9m and hepcidin in cynomolgus monkeys","volume":"12","author":"Xiao","year":"2010","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0760","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.immuni.2012.01.010","article-title":"JAK\u2019s SOCS: A mechanism of inhibition","volume":"36","author":"Yoshimura","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2021.107877_bb0765","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nchembio.2007.54","article-title":"Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism","volume":"4","author":"Yu","year":"2008","journal-title":"Nature Chemical Biology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821000796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821000796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:14:26Z","timestamp":1759011266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":153,"alternative-id":["S0163725821000796"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107877","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of hepcidin antagonists on anemia during inflammatory disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107877"}}